Congenital hyperinsulinism (CHI, MIM \#256450) is a heterogeneous disease with hyperinsulinemic hypoglycemia, most frequently caused by mutations in *ABCC8* ([@B1],[@B2]). Usher syndrome 1C (USH1C, MIM \#296904) is caused by mutations in *USH1C* ([@B3]), a gene situated next to *ABCC8* on chromosome 11p15.1. A very rare, homozygous contiguous gene deletion, including *USHIC* and *ABCC8*, has been described in three patients, characterized by severe CHI, deafness, vestibular hypofunction, severe enteropathy, and renal tubular dysfunction (MIM \#606528) ([@B4],[@B5]).

We report on 15 new patients from eight consanguineous families with the same homozygous deletion, but with clinical heterogeneity and with manifestations from β-cells, inner ear, and retina only.

RESEARCH DESIGN AND METHODS {#s1}
===========================

Among children with CHI in Riyadh and London, we identified 15 patients with severe congenital hearing loss. *USH1C*,*ABCC8*, and *KCNJ11* were analyzed by sequencing and multiplex ligation-dependent probe amplification (MLPA) (for details, see [Supplementary Figs. 1--4](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc12-1174/-/DC1)). Patient 3 was analyzed through two separate blood samples with additional sequencing of the nonsyndromic diabetes-related genes *HNF1A*,*HNF4A*,*GCK*,*INS*, and *INSR*. DNA microsatellite markers were used for haplotype analysis. Informed consent was obtained.

RESULTS {#s2}
=======

Fifteen patients from eight apparently unrelated, consanguineous families in Saudi Arabia and Kuwait were identified with deafness and CHI. Of these, 14 had severe CHI with need of subtotal pancreatectomy ([Table 1](#T1){ref-type="table"}). One patient (patient 3) had mild hypoglycemia only, which was diagnosed at 3 months of age. By 11 years, his HbA~1c~ level gradually increased to 8.5% (reference 4.4--6.4%), fasting blood glucose increased to 15 mmol/L, and postprandial hyperglycemia increased to 13 mmol/L. Serum insulin was low, 49 mU/L (reference 72--150 mU/L), blood glucose was 12.6 mmol/L, and 2-h oral glucose tolerance test (OGTT) glucose was 16 mmol/L. Autoantibodies were negative, and BMI was 21.6 kg/m^2^. No syndromic features were found and the mother had normal hearing, giving no clues for inheritance of syndromic diabetes mutations. The patient responded to metformin treatment.

###### 

Patient data

![](557tbl1)

Profound hearing loss with absent brain stem auditory-evoked response was diagnosed in all patients, with the exception of one who died early ([Table 1](#T1){ref-type="table"}). It is noteworthy that the atypical patient 3 also had severe hearing loss and developed retinitis pigmentosa at age 13 years. One other patient had retinal changes with absent visual-evoked response at 9.5 years. No patients had clinical evidence of vestibular dysfunction, prolonged diarrhea, vomiting, signs of renal tubular defects, or amino or organic acid in the urine.

None of the parents or other siblings had a history of hypoglycemia, diabetes, hearing loss, dizziness, vision anomalies, or signs of enteropathy or nephropathy. Parents had normal HbA~1c~ (5.2--6.0%), fasting blood glucose (4.8--6.7 mmol/L), and 2-h OGTT glucose (4.1--9.3 mmol/L), except one with 2-h OGTT glucose (12.5 mmol/L), which was explained by severe obesity (BMI 31 kg/m^2^).

In all 10 patients with available DNA, sequence analysis revealed a 122.815-base pair deletion of *USH1C* exon 3--28 and *ABCC8* exon 1--22, *USH1C*:c.(90+592)\_*ABCC8*: c.(2694--528)del. MLPA analyses confirmed the heterozygous state of the parents and the homozygous state of the offspring. In the atypical patient 3, the homozygous deletion was verified in two separate blood samples. No mutations were found in antagonizing, nonsyndromic diabetic genes. Microsatellite analysis in 12 parents showed a common ancestral haplotype. The mutation was calculated to be introduced in all the families approximately 3.9 generations previously for the parental generation.

CONCLUSIONS {#s3}
===========

We added 15 new patients to the only three patients already described with Usher-CHI syndrome and made a much longer follow-up until 16 years of age. Our data alter the phenotype description of the syndrome, not only in terms of a variable degree of hyperinsulinism with possibility of conversion to diabetes in the second decade but also in the Usher-related manifestations.

The deletion in *USH1C-ABCC8* was exactly the same in all the investigated patients as in the two previously reported families ([@B4],[@B5]) and calculated to be introduced in all six families studied approximately 3.9 generations before. Using an average generation time of 21.28 years in Saudi Arabia ([@B6]), this corresponds to a mutation age of 85 years.

In 14 patients, the hyperinsulinemic hypoglycemia was severe with early neonatal onset and did not respond to medical treatment, which is in line with the previous reports ([@B4],[@B5]) and three other patients described with *ABCC8* macrodeletions ([@B7],[@B8]). In contrast, one patient had very mild hypoglycemia only with conversion to diabetes in puberty, without any clue of mosaicism, type 1 diabetes, type 2 diabetes, or additional diabetes gene mutations. A homozygous *ABCC8* deletion is expected to result in a completely nonfunctional β-cell K~ATP~ channel ([@B9],[@B10]) as in mice SUR1 knockout ([@B11],[@B12]). However, SUR1^−/−^ and Kir6.2^−/−^ mice have mild, transient neonatal hyperinsulinism only, with rapid reversion to glucose intolerance and loss of insulin secretion in adulthood because of a lack of first-phase and an attenuated second-phase insulin secretion in response to glucose ([@B11]--[@B13]). Species differences include an attenuated β-cell--amplifying pathway in mice, suggesting that the amplifying pathway *1*) has an important role in producing severe and persistent hyperinsulinism in the patient with typical Usher-CHI syndrome and *2*) may be attenuated in the atypical mild patient.

The large *USH1C* homozygous deletion resulted in profound, congenital sensorineural deafness in all investigated patients, identical to the effect of reported *USH1C* point mutations ([@B3],[@B14]). Progressive retinitis pigmentosa is seen in *USH1C* patients with onset of nyctalopia (night blindness) from 7 to 15 years ([@B15]). Retinitis pigmentosa was diagnosed in two of our patients only because of young age. In *USH1C*, vestibular dysfunction may only be detected as absence of nystagmus on caloric stimulation ([@B15]) and was not detected in our patients, in contrast to the previous study ([@B5]). The three previously reported patients with Usher-CHI syndrome also had severe enteropathy and renal tubular defects ([@B4],[@B5]). Such manifestations were not seen in our patients and have not been reported in others with USH1 or CHI only, neither in *USH1C* knock-in or knockout mice nor in SUR1 knockout mice. It is suggested that the gut and renal manifestations in the previous reports were not the result of the homozygous deletion.

In conclusion, the phenotype of Usher-CHI syndrome is characterized by Usher 1 manifestations and a heterogeneous CHI pattern ranging from severe, persistent CHI to mild and transient hyperinsulinism with conversion to diabetes in the second decade.
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======================

###### Supplementary Data

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc12-1174/-/DC1>.
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